Khurram Jamil Sells 25,499 Shares of Galectin Therapeutics (NASDAQ:GALT) Stock

Galectin Therapeutics Inc. (NASDAQ:GALT) insider Khurram Jamil sold 25,499 shares of the stock in a transaction on Monday, January 5th. The shares were sold at an average price of $3.90, for a total value of $99,446.10. Following the completion of the transaction, the insider owned 21,446 shares of the company’s stock, valued at $83,639.40. This trade represents a 54.32% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Khurram Jamil also recently made the following trade(s):

• On Tuesday, January 6th, Khurram Jamil sold 21,446 shares of Galectin Therapeutics stock. The shares were sold at an average price of $3.65, for a total transaction of $78,277.90.
• On Friday, January 2nd, Khurram Jamil sold 13,055 shares of Galectin Therapeutics stock. The stock was sold at an average price of $4.20, for a total transaction of $54,831.00.
• On Wednesday, December 17th, Khurram Jamil sold 19,442 shares of Galectin Therapeutics stock. The stock was sold at an average price of $7.04, for a total transaction of $136,871.68.
• On Thursday, November 13th, Khurram Jamil sold 121,117 shares of Galectin Therapeutics stock. The shares were sold at an average price of $5.47, for a total transaction of $662,509.99.

Galectin Therapeutics Price Performance

Galectin Therapeutics stock traded down $0.43 during midday trading on Tuesday, reaching $3.45. The stock had a trading volume of 905,529 shares, compared to its average volume of 684,117. Galectin Therapeutics Inc. has a twelve month low of $1.07 and a twelve month high of $7.13. The firm has a market cap of $222.42 million, a price-to-earnings ratio of -5.85 and a beta of 1.03. The firm’s fifty day simple moving average is $5.34 and its two-hundred day simple moving average is $4.39.

Galectin Therapeutics (NASDAQ:GALT) last released its earnings results on Friday, November 14th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). As a group, sell-side analysts predict that Galectin Therapeutics Inc. will post -0.73 EPS for the current fiscal year.

Institutional Investors Weigh In On Galectin Therapeutics

A number of large investors have recently bought and sold shares of GALT. Wealthspire Advisors LLC increased its position in Galectin Therapeutics by 20.4% during the second quarter. Wealthspire Advisors LLC now owns 479,518 shares of the company’s stock worth $1,012,000 after buying an additional 81,144 shares during the last quarter. Truist Financial Corp bought a new stake in shares of Galectin Therapeutics during the 2nd quarter worth about $143,000. Geneos Wealth Management Inc. increased its holdings in shares of Galectin Therapeutics by 8.8% during the 1st quarter. Geneos Wealth Management Inc. now owns 423,235 shares of the company’s stock valued at $516,000 after acquiring an additional 34,300 shares during the last quarter. Stratos Wealth Partners LTD. raised its stake in shares of Galectin Therapeutics by 17.8% in the 2nd quarter. Stratos Wealth Partners LTD. now owns 60,750 shares of the company’s stock valued at $128,000 after acquiring an additional 9,200 shares in the last quarter. Finally, Nuveen LLC acquired a new stake in Galectin Therapeutics in the 1st quarter worth approximately $34,000. 11.68% of the stock is currently owned by institutional investors.

Galectin Therapeutics News Summary

Here are the key news stories impacting Galectin Therapeutics this week:

• Negative Sentiment: CEO Joel Lewis sold multiple blocks of stock (Jan. 2, Jan. 5 and Jan. 6), totaling 83, (serial sales of 18,571; 27,731; 37,698 shares) at average prices around $4.20–$3.58, reducing his stake by ~4% overall — signaling significant insider liquidity. CEO Joel Lewis Form 4
• Negative Sentiment: CFO Jack W. Callicutt also executed staged sales (Jan. 2, Jan. 5 and Jan. 6), selling roughly 59, (13,914; 25,732; 20,354 shares) at avg. prices ~$4.20–$3.67, cutting his direct holdings by a large percentage — another material insider reduction. CFO Jack W. Callicutt Form 4
• Negative Sentiment: Director/insider Khurram Jamil sold multiple tranches (Jan. 2, Jan. 5 and Jan. 6) totaling ~60,000+ shares across those dates at avg. prices from $4.20 to $3.65, substantially reducing his position — further insider selling pressure. Khurram Jamil Form 4
• Negative Sentiment: Pomerantz LLP announced an investor investigation into Galectin on Jan. 6, which can increase legal risk and heighten short‑term selling pressure. Pomerantz Investor Alert

Analyst Ratings Changes

A number of research firms have recently issued reports on GALT. HC Wainwright increased their price target on shares of Galectin Therapeutics from $6.00 to $11.00 and gave the stock a “buy” rating in a research report on Wednesday, December 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Galectin Therapeutics in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $11.00.

About Galectin Therapeutics

Galectin Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel therapies that target galectin proteins, which are implicated in fibrotic, inflammatory and malignant diseases. The company’s lead product candidate, belapectin (formerly GR-MD-02), is a galectin-3 inhibitor being evaluated in Phase 2 clinical trials for nonalcoholic steatohepatitis (NASH) with cirrhosis. In addition to its core pipeline in fibrotic liver disease, Galectin Therapeutics continues to explore the potential of its galectin inhibitors in oncology and other indications driven by abnormal tissue remodeling.

Founded in 2000, the company is headquartered in Norcross, Georgia, where it oversees discovery research, preclinical studies and clinical trial coordination.